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Background > Survival of metastatic colon cancer (mCC) patients has considerably improved with
optimization of new drugs regimen. Inactivation of TP53 pathway by TP53 mutations is observed in
nearly half of colorectal tumors. The impact of such mutations has been poorly studied in the
metastatic setting.
Methods > The files of 254 mCC treated in a single institution at Saint-Louis hospital between
January 1999 and April 2011 were retrospectively reviewed. Tissue samples for analysis of TP53
mutations were available for 68 patients, performed using FASAY. The prognostic value of TP53
status was evaluated by comparing progression free survival (PFS) and overall survival (OS) in the
group of TP53-mutated and wild type patients.
Results > PFS was 6.9 months and OS 21.7 months in the whole population. There was no statistical
difference in TP53-mutated and wild type groups in term of PFS (HR = 1.04; IC9 5% = 0.6–1.79) and
OS (HR = 0.99; IC 95% = 0.53–1.55) whatever the chemotherapy regimen (oxaliplatin- or irino-
tecan-based). Only BRAF V600 mutation was demonstrated to be a poor prognostic factor for PFS
and OS, and CEA level for OS.
Conclusions > Routine determination of TP53 mutations, even with a highly sensitive method,
cannot be recommended to predict chemotherapy response in mCC.
 Elsevier Masson SAS. All rights reserved.
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Résumé
Les mutation du gène TP53 n'ont pas d'impact sur la réponse aux agents cytotoxiques
dans le cancer du côlon metastatique
Objectifs > Les avancées dans les modalités de traitement du cancer colorectal ont permis une
amélioration du pronostic notamment dans le cancer colorectal métastatique (CCRm). Notre
étude visait à étudier l'intérêt de la recherche des mutations de p53 dans la réponse à la
chimiothérapie en situation métastatique.
Patients et méthodes > Il s'agit d'une étude rétrospective monocentrique portant sur 68 patients
suivis à l'hôpital Saint-Louis entre janvier 1999 et avril 2011, présentant un cancer colique méta-
statique (CCm) pour lesquels un statut p53 avait été réalisé par méthode FASAY. Nous avons étudié
la survie sans progression et la survie globale de ces patients en fonction du statut p53.
Résultats > La survie sans progression (SSP) était de 6,9 mois et la survie globale (SG) de
21,7 mois. Il n'y avait pas de différence signiﬁcative sur la SSP (HR = 1,04; IC 95 % = 0,6–
1,79) et sur la SG (HR = 0,99; IC 95 % = 0,53–1,55) entre les groupes TP53 mutés et sauvages
quelque soit le type de chimiothérapie reçue (oxaliplatine ou irinotecan). La mutation BRAF
V600 et le taux d'ACE sont les seuls facteurs de mauvais pronostique retrouvés.
Conclusion > La determination du statut p53 ne permet pas de prédire la réponse à la chimio-
thérapie dans le CCm.
J. Netter, J. Lehmann-Che, J. Lambert, A. Tallet, N. Lourenco, H. Soliman, et al.
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In Europe, colorectal cancer (CRC) represents the second most
common cause of cancer with 436,000 cases diagnosed in
2008 with a high mortality estimated at 1,212,000 cases [1].
About 40% of patients have a metastatic disease at diagnosis [2].
Metastatic colorectal cancer (mCRC) prognosis has considerably
improved with optimization of administration of 5-FU, introduc-
tion of oxaliplatin and irinotecan, and more recently of targeted
therapies, such as anti-VEGF (vascular endothelial growth factor)
(bevacizumab) and anti-EGFR (epidermal growth factor receptor)
(cetuximab, panitumumab). Prediction of chemotherapy
response using biological markers has emerged as a key pointGlossary
mCC metastatic colon cancer
CRC colorectal cancer
mCRC metastatic colorectal cancer
PFS progression free survival
OS overall survival
FASAY functional analysis of separated alleles in yeast
HR hazard ratio
PS performance status
CI confidence interval
EGFR epidermal growth factor
VEGF vascular endothelial growth factor
MSI microsatellite instability
5-FU 5-fluorouracil
CEA carcinoembryonic antigenein mCRC. Despite extensive research, there is no predictive bio-
marker of response to standard therapies and bevacizumab in
routine practice. To date, KRAS mutation is the only validated
predictive factor of non-response to anti-EGFR therapy leading to
contra-indication to its use in such situation [3]. Mechanisms of
colorectal carcinogenesis involve multiple tumor suppressor
genes (APC, TP53, TGF-b) [4] and oncogenic genes (RAS, BRAF,
PTEN and PIK3CA). Inactivation of TP53 pathway by TP53 muta-
tions is present in nearly half of colorectal tumors [5], and is one of
the key genetic steps in colorectal carcinogenesis. P53 protein is a
transcription factor, which exerts multiple antiproliferative func-
tions. TP53 pathway is activated in stressful situations and leads,
depending on the intensity of the damage, to cell cycle arrest to
allow DNA repair, senescence or death of the cell by induction of
apoptosis [6–8]. Loss of function of TP53 in cells, by mutations,
promotes development of cancer. For twenty years, TP53 gene
has been extensively studied as a prognostic and predictive
marker in colorectal cancer. These studies have focused on located
CRC with conflicting results. Several hypotheses can explain those
discrepancies. Various methods of detection of TP53 mutations
have been reported. The most frequent techniques were immu-
nohistochemistry and TP53 sequencing but they raised some
criticism. There is currently no solid data supporting the interest
of TP53 mutations analysis regardless of the chemotherapy regi-
men used. In this study, the analysis of the TP53 status was
performed by Functional Analysis of Separated Alleles in Yeast
(FASAY), a method allowing the functional evaluation of the p53
protein followed by the characterization of the identified alter-
ation by sequencing [9]. We used routinely this technology intome 102 > n82 > février 2015
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sensitivity, over 90% of TP53 mutations [12]. The aim of our study
was to evaluate the predictive value of TP53 mutations using
FASAY in mCC. We have planned a subgroup analysis according to
the functional implication of each mutation. The other biological
markers currently known to be involved in colorectal carcinogen-
esis have been also studied to determine if a subgroup of molec-
ular profile emerged.
Methods
Patients
We retrospectively reviewed 362 consecutive medical charts of
patients treated for metastatic colorectal cancer at Saint-Louis
University Hospital (Paris, France) between January 1999 and April
2011. We excluded all the patients with rectal cancer (n = 108) to
have a homogeneous profile of treatment. We included only
patients with complete clinical data and available TP53 status.
In cases of incomplete molecular data, if possible, frozen tissue
samples were retrieved from the pathology department and TP53
status and other molecular analyses were performed retrospec-
tively. Finally, we included 68 patients with TP53 status available
by FASAY method on resected primary tumor or metastasis.
Samples were provided by the biological resource center after
approval of the Saint-Louis hospital ethical review board (Paris,
France: agreement no DC 2009-929), following the Ethics and
Legal National French rules for the patients' information and
consent (ANAES, HAS and INCa). All patients were informed of
the study and did not oppose to it, according to our Institutional
Review Board recommendations.
TP53 mutation analysis
Mutational analysis of TP53 was performed using FASAY, in
accordance to the method described by Flaman et al. [9].
This method requires frozen tumor samples to obtain high
quality of RNA to evaluate the transactivation activity of the
corresponding p53 protein on a p53-responsive promoter stably
integrated in the yeast genome. RNA was extracted by phenol–
chloroform method, reverse transcribed and p53 transcripts
were amplified by PCR and co-transfected into yeast with the
Gap repair plasmid. The corresponding TP53 sequence is
expressed in the yeast and directs the growth and the color
of the yeast colonies. Yeast colonies transformed with wild type
or mutated TP53 sequences appear white and large, or red and
small, respectively. TP53 status was considered non-functional if
more than 15% of the yeast colonies were red and if confirmed
by the split versions of the test (defect in the 50 and/or 30 part of
the gene). After identification of non-functional TP53 samples or
in cases of "borderline'' FASAY results (between 10% and 15% of
red colonies), red colonies were cloned and sequenced by
Sanger method to characterize the TP53 mutation.
Finally, we classified the mutations into two groups using the
IARC p53 database according to their impact on the protein:tome 102 > n82 > février 2015presence of a modified p53 protein (p-MOD) and absence of a
p53 protein (p-NO) [13].
Other mutations analysis
DNA was extracted from selected sections of the tumor samples
(presence of > 30% tumor cells) after overnight proteinase K
digestion, using the QIAamp DNA minikit (Qiagen) according to
manufacturer's instructions.
The seven KRAS mutations on codon 12 and 13 were analyzed
by allelic discrimination: specific probes for each allele (mutated
or wild type) were labeled with fluorescent reporter dyes at
their 50 end and analysed by real-time PCR on a LC480 (Roche)
[14].
The BRAF V600E mutation status was also assessed by allelic
discrimination on a LC480 (Roche) [15]. PIK3CA (exon 20) gene
was analyzed by HRM (LC480 Roche) and the defect was iden-
tified by sequencing on a sequencer 3130 (Applied) in case of
abnormal HRM profile. For all samples and all genotyping, a
second independent analysis was performed to confirm the final
result. Primers, probes and PCR conditions are available upon
request.
To evaluate microstatellite instability (MSI), a pentaplex PCR,
comprising five quasimonomorphic mononucleotide repeats
(BAT-25, BAT-26, NR-21, NR-24, and NR-27) was used [16].
Tumors with instability at  3 markers were defined as MSI-
H, whereas those with < 3 as MSI-L or MSS if any instability.
Statistical methods
Results were expressed as frequency with percentages for
categorical variables, and median with interquartile range
(IQR) for quantitative variables. Patients' characteristics accord-
ing to p53 status were compared using Fisher's exact test and
Wilcoxon rank sum test. Overall survival (OS) was defined as the
time between diagnosis of metastatic disease and death from
any cause. Progression free survival (PFS) was defined as the
time between first metastatic chemotherapy cure and first
documentation of tumor progression (date of CT scan or surgery)
or death from any cause. The closing date for the analysis was
2012/07/01. OFS and PFS according to p53 status were plotted
using the Kaplan–Meier survival estimator and compared using
the log-rank test. The effect of several candidate prognostic
factors on overall survival was assessed using a Cox proportional
hazard regression model and presented by the hazard ratio (HR)
and its 95% confidence interval. Analysis was performed using R
2.10.1. All statistical tests were two-sided with P-values lower
than 0.05 considered as significant.
Results
Patient's population and tissue specimen
Study population consisted of 68 patients treated for metastatic
colon cancer. Patients were predominantly males (51%), and
median age at diagnosis was 62 years (range 53–74 years) with
performance status (PS)  2 in 90% of the cases. Primary tumor11
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TABLE II
Metastatic chemotherapy regimensa
Chemotherapy regimens n = 61 patients
First-line regimens
5-FU + oxaliplatin 36 59%
5-FU + irinotecan 10 16%
5-FU 4 7%
Cetuximab (5-FU + oxaliplatin
or irinotecan)
4 7%
Bevacizumab (5-FU+ oxaliplatin
or irinotecan)
7 12%
All lines regimens
J. Netter, J. Lehmann-Che, J. Lambert, A. Tallet, N. Lourenco, H. Soliman, et al.
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cases. Metastases were synchronous in 68% of the cases. Sev-
enty-one percent of patients had one metastatic site, mainly
hepatic (69%) (table I). First-line of chemotherapy contained 5-
fluoro-uracile (5-FU) in all cases with oxaliplatin (59%) or iri-
notecan (16%) (table II). Only 11 patients received cetuximab
(6%) or bevacizumab (11%) in association with irinotecan- or
oxaliplatin-based regimen. Seven patients received exclusive
base supportive care because of poor condition. Other histologi-
cal prognostic data (vascular, lymphocytic and perineural inva-
sion) collected from pathology reports could not be analyzed
due to the large number of missing data. TP53 status was mostly
obtained in primary tumor site (n = 62) and rarely metastasis
(n = 6).5-FU 61 100%
Oxaliplatin 53 87%
Irinotecan 43 70%
Anti-EGFR therapies 21 34%
Anti-VEGF therapies 25 40%
Number of lines
1 17 25%
2 18 27%
3 16 24%
4 or more 10 15%
aBase supportive care alone: n = 7.
TABLE I
Patient and tumor characteristics.
Caracteristics n = 68 patients
Age (years) 62.4 [53.5–74]
Gender
Male 35 51%
Female 33 49%
PS
0–2 61 90%
> 2 7 10%
Metastasis
Synchronous 46 68%
Metachronous 22 32%
Number of metastatic sites
1 49 72%
> 1 19 28%
Metastasis
Liver 47 69%
Lung 7 10%
Carcinomatosis 19 28%
Differentiationa
Poor/moderate 29 51%
Well 28 49%
CEA
Informative 45 69%
Data are presented as frequency (percentage) or median [25th–75th percentiles]. PS:
performance status; CEA: carcinoembryonic antigene.
aMissing data: n = 10.TP53 mutations of the tumors
TP53 status could be determined for 68 patients. A non-func-
tional TP53 status was found in 38 patients (56%). There was no
evidence of heterogeneity in patients' characteristics (age, sex,
PS status, tumor differentiation, number and type of metastasis,
molecular factors) between the TP53-mutated and the TP53-
wild type group of tumors (table III). We identified the TP53
alteration leading to non-functional FASAY by sequencing in
36 cases, and recorded the types of mutation according to
the IARC p53 database. Six patients presented a tumor with a
mutation leading to absence of p53 protein (P-NO), and
30 patients a mutation leading to the presence of a mutated
p53 protein with potential new functions (P-MOD). We failed to
perform sequencing for 2 patients.
Other mutation analysis
Microsatellite instability was found in 23% of patients (12 MSI-L
patients, 4 patients MSI-H), KRAS mutation in 48% of patients
(mutations found: 7 G12A, 7 G12V, 6 G12D, 4 G12C, 2 G12S,
9 G13D), BRAF mutation in 9% of patients, and PIK3CA mutationtome 102 > n82 > février 2015
TABLE III
Patient and tumor characteristics according to p53 status.
TP53-mutated (n = 38) TP53-wild type (n = 30) P value
Age (years) 62 [55–75] 63 [55–72] 0.956
Gender
Male 21 (55%) 14 (47%) 0.626
Female 17 (45%) 16 (53%)
PS
0–2 35 (92%) 26 (87%) 0.691
> 2 3 (8%) 4 (13%)
Metastasis
Synchronous 24 (63%) 22 (73%) 0.44
Metachronous 14 (37%) 8 (27%)
Differentiation
Poor 0 (0%) 2 (8%) 0.364
Moderate 16 (50%) 11 (44%)
Well 16 (50%) 12 (48%)
Metastasis
Liver 26 (69%) 21 (70%) 1
Lung 2 (5%) 5 (17%) 0.227
Carcinomatosis 10 (26%) 9 (30%) 0.79
Lymph nodes 4 (10%) 3 (10%) 1
Other 9 (24%) 3 (10%) 0.0723
Molecular factor
KRAS mutated 17 (46%) 16 (53%) 0.627
BRAF mutated 2 (6%) 4 (13%) 0.407
PIK3CA mutated 1 (3%) 4 (13%) 0.177
MSI-H and L 8 (22%) 8 (28%) 0.773
CEA
Informative 24 (69%) 20 (69%) 1
Data are presented as frequency (percentage) or median [25th–75th percentiles]. PS: performance status; CEA: carcinoembryonic antigene; KRAS mutated: Kirsten rat sarcoma 2 viral
oncogene homolog (c-Ki-ras2) codons 12 and 13, BRAF mutated: v-Raf murine sarcoma viral oncogene homolog B1 V600E; PIK3CA: mutated: phosphatidylinositol-4,5-bispho-
sphonate3-kinase exon 20; MSI-H and L: microsatellite instability-high and low.
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determined in some cases because of a lack of material (MSI
status in 2 patients, KRAS in 1 patient, BRAF in 4 patients, and
PIK3CA in 4 patients).Progression free survival analysis
At the time of statistical analysis, 5 patients were still in first-line
chemotherapy and 49 patients had progressed. Seven patientstome 102 > n82 > février 2015had stopped chemotherapy in first-line because of an impaired
general condition. Median PFS was 6.9 months.
PFS was not significantly different between the TP53-wild type
(WT) and mutated groups (MUT) (HR = 1.04; IC 95% = 0.6–1.79),
and between the 3 groups wild type, p-MOD (HR = 0.92; IC 95%
= 0.51–1.64) and p-NO (HR = 1.62; IC 95% = 0.65–4.04) (ﬁg-
ure 1). We did not find any mutation effect on PFS according
to the type of chemotherapy received (oxaliplatin- or irinotecan-
based) (HR = 1.45; IC 95% = 0.76–2.75) (ﬁgure 2).12
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Figure 1
Log-rank curve of progression free survival according to p53 status
A. Progression free survival according to p53 status.
B. Progression free survival according to p53 mutation type.
P53 WT: wild type p53 protein.
P53-MOD: gain of function or dominant.
P53-NO: absence of protein p53.
Figure 2
Log-rank curve of disease free survival according to p53 status and type of first-line chemotherapy regimen
A. Oxaliplatin-based chemotherapy.
B. Irinotecan-based chemotherapy.
J. Netter, J. Lehmann-Che, J. Lambert, A. Tallet, N. Lourenco, H. Soliman, et al.
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TABLE IV
Univariate analysis of prognostic factors for overall survival.
Variables HR 95% CI P value
PS
0–2 vs > 2 1.1 [0.47–2.59] 0.826
Number of metastatic sites
1 vs > 1 1.19 [0,68–2,08] 0.539
Function of sites number 1.15 [0.76–1.74] 0.524
Chemotherapy
Mono/bitherapy vs tritherapy 1.79 [0,88–3,65] 0,126
CEA
Informative 1.94 [1,01–3.75] 0.037
Differentiation
Poor/moderate vs well 1.73 [0.96–3.14] 0.069
Metastasis
Metachronous vs synchronous 1.54 [0.83–2.87] 0.184
P53
Mutated vs wild type 0.99 [0.53–1.55] 0.73
KRAS
Mutated vs wild type 1.17 [0.69–1.99] 0.561
BRAF
Mutated vs wild type 3.5 [1.45–8.44] 0.0153
PIK3CA
Mutated vs wild type 0.79 [0.28–2.21] 0.646
MSI
MSI-H vs MSI-L/MSS 1.84 [0.65–5,18] 0.286
Type of chemotherapy
Irinotecan 1.08 [0.34–3,4] 0.933
Oxaliplatin 0.95 [0.32–2,81]
PS: performance status; CEA: carcinoembryonic antigene; KRAS mutated: Kirsten rat
sarcoma 2 viral oncogene homolog (c-Ki-ras2) codons 12 and 13, BRAF mutated: v-
Raf murine sarcoma viral oncogene homolog B1 V600E; PIK3CA: mutated: phospha-
tidylinositol-4,5-bisphosphonate3-kinase exon 20; MSI-H and L: microsatellite
instability-high and low.
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At the time of statistical analysis, 57 patients (83%) had died.
The median OS was 21.7 months. There was no significant
difference in OS between TP53-mutated and wild type groups
(HR = 0.99; IC 95% = 0.53–1.55).
We did not find any mutation effect on OS depending on the
type of chemotherapy received (oxaliplatin versus irinotecan)
(HR = 0.9; IC 95% = 0.47–1.7).
Univariate analysis of prognostic factors
Prognostic factors studied in univariate analysis were: PS status,
degree of differentiation of the primary tumor, number of meta-
static sites at metastasis diagnosis, type of chemotherapy, CEA,
KRAS, PIK3CA and BRAF mutation, TP53 and MSI status. Among
molecular factors, only BRAF V600 mutation was a poor prognostic
factor for PFS (HR = 3.3, 95% CI = 1.12–6.56) and OS (HR = 3.5;
95% CI = 1.45–8.44, P = 0,015). Elevated level of CEA (upper than
normal value of analysis laboratory) at diagnosis was also a poor
prognostic factor for OS (HR = 1.94; 95% CI = 1.01–3.75) (table IV).
Discussion
Determination of prognostic and predictive factors of response
to colorectal cancer treatment has been studied extensively for
several years. Some genetic polymorphisms have been corre-
lated to irinotecan and 5-FU toxicities. A recent study suggests
a correlation between some of these polymorphisms and
tumor response to 5-FU and oxaliplatin [17]. However, the most
significant advances have occurred in the molecular biology
field. KRAS mutation has been widely shown as predictive of
anti-EGFR inefficacy [3]. More recently, BRAF mutation has been
clearly shown to be a poor prognostic factor for patients with
mCRC [18]. Thus, in a recent randomized trial comparing 3 arms
of treatment with 5-FU and oxaliplatin plus or minus cetuximab,
BRAF mutation was associated with significantly poorer OS (9.5
vs 22.0 months) [19]. As well, double mutations of exon 9 and
20 of PIK3CA have been shown to be a poor prognostic factor of
survival in 2 large prospective cohorts of colorectal patients
[20]. Additionally, null expression of PTEN has been correlated
with poor overall survival in the subgroup of KRAS wild type
patients [18]. TP53 tumor suppressor gene is involved in the
development of many human cancers and crucial in response to
DNA damages. Understanding various functions and interac-
tions of p53 with other intracellular pathways is still unclear
despite several decades of research on this topic. In addition,
there are over 900 mutations with different functional impact
making interpretation of the mutational status difficult. Many
studies have investigated prognostic and predictive impact of
the TP53 status on different cancer contexts. Especially, we
have previously shown, in breast cancer, that the presence of
TP53 mutation improved response to high doses of anthracy-
clines and cyclophosphamide as neoadjuvant therapy in locally
advanced non-inflammatory breast cancer [21]. However,tome 102 > n82 > février 2015impact of TP53 gene mutation on CRC natural history and its
possible interaction with response to chemotherapy remains
controversial. One explanation is the variability of methods
used to determine the p53 status. The two most common
techniques used are immunohistochemistry (IHC) and sequenc-
ing. IHC is a technique that evaluates the TP53 status by
detecting p53 protein stabilization as consequence of some,
but not all, TP53 mutations. IHC positivity correlates with TP53
mutations in only 80% of cases. On the other hand, sequencing
is usually performed only for a part of TP53 gene (usually exon12
3
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of their impact on the protein functionality.  Results of a large
number of studies about prognostic impact of TP53 mutations
on survival and predicting response to adjuvant chemotherapy
are still debatable [22–24]. As well, results of the few studies
about the predictive value of TP53 mutations in mCRC are
disappointing [25,26]. Discordant data were reported in old
series regarding the impact of TP53 mutation in 5-FU treated
patients. TP53 mutations do not seem to be predictive of tumor
response in folfox regimen and bevacizumab-based treatment
[27,28]. One study has suggested that TP53 mutation was
correlated with tumor response in WT KRAS patients receiving
cetuximab-based chemotherapy [29]. There is no data on the
potential role of TP53 mutation in patients treated with irino-
tecan-based regimen.
One strength of our work is represented by determination of
TP53 mutation with a sensitive and functional assay (FASAY) and
the systematic characterization of TP53 mutation by sequenc-
ing. We evaluated the impact of the presence of a mutated p53
protein with potentially new functions (p53-MOD) or the
absence of the protein (p53-NO) on the prognostic and the
response to treatment. No implication of the TP53 status has
been highlighted, but we cannot exclude that our relatively
small patient cohort do not allow final conclusions.
Finally, our study does not support the interest of determining
TP53 status in mCC whatever the chemotherapy administered.
These negative results are not influenced by patient's heteroge-
neity. There was no difference in the characteristics of the popu-
lation in the two groups of TP53-mutated and wild type patients.References
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